Quizartinib (AC220): A Breakthrough FLT3 Inhibitor for AML
Discover the potent therapeutic potential of Quizartinib in targeting FLT3 mutations for Acute Myeloid Leukemia.
Get a Quote & SampleProduct Core Value
Quizartinib
Quizartinib, also known as AC220, is a second-generation FLT3 inhibitor that demonstrates remarkable potency and selectivity. It is specifically designed to target Flt3 (ITD/WT) mutations, which are prevalent in Acute Myeloid Leukemia (AML). Its mechanism of action involves inhibiting FLT3 kinase activity, thereby blocking downstream signaling pathways crucial for leukemic cell proliferation and survival. Preclinical and clinical studies have shown its significant promise in inducing apoptosis and exhibiting antitumor properties.
- Introduction to Quizartinib for Acute Myeloid Leukemia: Explore how this potent FLT3 inhibitor offers a novel therapeutic avenue for patients with FLT3-ITD positive AML.
- Understanding the Quizartinib Mechanism of Action: Delve into how AC220 selectively targets FLT3, leading to cell cycle arrest and apoptosis in cancer cells.
- Key Applications of Quizartinib: Learn about its use in treating AML and its potential in other FLT3-related cancers.
- The Role of Quizartinib in Targeted Therapy: Understand how Quizartinib exemplifies advancements in precision medicine for hematological malignancies.
Product Advantages
High Selectivity and Potency
Quizartinib exhibits a significantly higher selectivity for FLT3 over other kinases, demonstrating potent IC50 values in cellular assays, making it a precise tool for FLT3-targeted therapy.
Effective Against FLT3 Mutations
Its efficacy is particularly noted in AML patients with FLT3 internal tandem duplication (ITD) mutations, a common driver in aggressive forms of the disease, offering a targeted approach to treatment.
Induces Apoptosis and Cell Death
The compound effectively induces apoptosis in tumor cells, a critical mechanism for eliminating cancer cells and a key factor in its antitumor properties observed in vivo.
Key Applications
Acute Myeloid Leukemia (AML) Treatment
Primary application is in the treatment of AML, particularly for patients with FLT3-ITD positive mutations, as part of combination therapy.
Oncology Research
Used in research settings to study FLT3 signaling pathways, drug resistance mechanisms, and to develop new anti-cancer strategies.
Pharmaceutical Intermediate
Serves as a critical pharmaceutical intermediate in the synthesis of advanced therapeutic agents for various oncological applications.
Targeted Therapy Development
A key compound in the development of targeted therapies, offering a model for selective kinase inhibition in cancer treatment.